Company profile for Tessa Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Tessa’s R&D is based on over three decades of research and development by our Scientific Co-Founder, and internationally recognized clinical scientist, Dr. Malcolm Brenner. His research has shown that the body’s anti-viral immune response can be harnessed as a potent therapy for cancer treatment. Our core platform technology uses a specific subset of immune cells known as Virus-Specific T cells (VSTs) – it has shown comp...
Tessa’s R&D is based on over three decades of research and development by our Scientific Co-Founder, and internationally recognized clinical scientist, Dr. Malcolm Brenner. His research has shown that the body’s anti-viral immune response can be harnessed as a potent therapy for cancer treatment. Our core platform technology uses a specific subset of immune cells known as Virus-Specific T cells (VSTs) – it has shown compelling results in the treatment of solid tumors in clinical trials.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Singapore
Address
Address
8 Temasek Boulevard,24-02 Suntec Tower 3- 038988
Telephone
Telephone
65 6384 0755
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Tessa Therapeutics dissolves after raising more than $200M
Tessa Therapeutics dissolves after raising more than $200M

06 Jul 2023

// Max Bayer FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/tessa-therapeutics-dissolves-after-raising-more-200m

Max Bayer FIERCE BIOTECH
06 Jul 2023

https://www.globenewswire.com/news-release/2023/06/16/2689643/0/en/Tessa-Therapeutics-Announces-Positive-Results-from-CD30-CAR-T-Combination-Study-with-Nivolumab-in-2nd-line-Hodgkin-Lymphoma.html

GLOBENEWSWIRE
16 Jun 2023

https://www.globenewswire.com/news-release/2023/06/16/2689488/0/en/Tessa-Therapeutics-Off-the-Shelf-CAR-T-Therapy-Shows-Promising-Results-in-Early-Stage-Study-of-Hodgkin-Lymphoma.html

GLOBENEWSWIRE
15 Jun 2023

https://www.globenewswire.com/news-release/2023/05/30/2678126/0/en/Tessa-Therapeutics-Autologous-and-Allogeneic-Cell-Therapy-Data-to-be-Featured-at-the-17th-International-Conference-on-Malignant-Lymphoma-Lugano.html

GLOBENEWSWIRE
30 May 2023

https://www.globenewswire.com/news-release/2023/03/08/2622756/0/en/Tessa-Therapeutics-Enters-into-Cooperative-Research-and-Development-Agreement-CRADA-with-the-U-S-National-Cancer-Institute.html

GLOBENEWSWIRE
08 Mar 2023

https://www.contractpharma.com/contents/view_breaking-news/2023-03-08/tessa-therapeutics-enters-crada-with-the-national-cancer-institute/?widget=listSection

CONTRACT PHARMA
08 Mar 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty